Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Go back to Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090| AKEBIA THERAPEUTICS (NASDAQ: AKBA) | Delayed: 1.11 +0.02 (1.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.09 | 52 Week High | $13.20 | |||
| Open | $1.09 | 52 Week Low | $7.00 | |||
| Day High | $1.14 | P/E | N/A | |||
| Day Low | $1.09 | EPS | $0.00 | |||
| Volume | 892,954 | |||||
